Johnson & Johnson's Q3 2014 earnings exceeded expectations, with strong EPS growth and increased full-year guidance. While future OLYSIO sales may face headwinds due to new competition, the company's robust performance across other key products and positive comments on market trends suggest continued strength. The upbeat earnings and raised guidance are likely to positively impact the stock in the short term.

[1]